Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 122

Sort by

Sort Order Select

Journal Articles

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Blood (2024) 144 (15): 1570–1580.

https://doi.org/10.1182/blood.2023023754

Published: 2024

Includes: Supplemental data

Journal Articles

Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1 + acute lymphoblastic leukemia

Pierre Walczak, Sofiane Fodil, Nicolas Vignal, Aurélie Cabannes-Hamy, Nicolas Boissel, Emmanuel Raffoux, Jean-Michel Cayuela, Lauriane Goldwirt, Etienne Lengliné

Blood (2024) 144 (10): 1127–1130.

https://doi.org/10.1182/blood.2024024838

Published: 2024

Journal Articles

Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

Blood (2024) 144 (9): 988–1000.

https://doi.org/10.1182/blood.2023022154

Published: 2024

Includes: Supplemental data

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

Hippolyte Guerineau, Jean-Michel Cayuela, Stéphanie Dulucq, Violaine Tran Quang, Sihem Tarfi, Quentin Barathon, Corine Joy, Orianne Wagner-Ballon, Stéphane Morisset, Franck E. Nicolini, Lydia Roy, Sébastien Maury, Gabriel Etienne, Delphine Rea, Ivan Sloma

Blood (2023) 142 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2023-186271

Published: 2023

Journal Articles

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Blood (2023) 142 (Supplement 1): 844.

https://doi.org/10.1182/blood-2023-179298

Published: 2023

Journal Articles

Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL

Blood (2023) 142 (Supplement 1): 2980.

https://doi.org/10.1182/blood-2023-185831

Published: 2023

Journal Articles

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Blood (2023) 141 (11): 1353–1358.

https://doi.org/10.1182/blood.2022017755

Published: 2023

Includes: Supplemental data

Journal Articles

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

Stephanie Dulucq, Frédéric Bauduer, Jean-Michel Cayuela, Patrice Chevallier, Pascale Cony-Makhoul, Yannick Le Bris, Laurence Legros, Herve Maisonneuve, Lydia Roy, Francois-Xavier Mahon, Sandrine Hayette, Delphine Rea, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 2556.

https://doi.org/10.1182/blood-2021-149986

Published: 2021

Journal Articles

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Franck E. Nicolini, Vincent Alcazer, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Stephane Morisset, Christophe Bouvier, Francois-Xavier Mahon, Gabriel Etienne, Delphine Rea

Blood (2021) 138 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2021-146722

Published: 2021

Journal Articles

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Blood (2021) 138 (Supplement 1): 512.

https://doi.org/10.1182/blood-2021-148843

Published: 2021

Journal Articles

Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial

Blood (2021) 138 (Supplement 1): 3478.

https://doi.org/10.1182/blood-2021-150126

Published: 2021

Journal Articles

IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL

Mathieu Simonin, Ludovic Lhermitte, Marie-Emilie Dourthe, Etienne Lengliné, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Isabelle Arnoux, Virginie Gandemer, Norbert Ifrah, Hervé Dombret, André Baruchel, Elizabeth Macintyre, Arnaud Petit, Nicolas Boissel, Vahid Asnafi

Blood (2021) 137 (12): 1690–1694.

https://doi.org/10.1182/blood.2020007959

Published: 2021

Includes: Supplemental data

Journal Articles

Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia

Florian Chevillon, Emmanuelle Clappier, Chloé Arfeuille, Jean-Michel Cayuela, Jean Hugues Dalle, Rathana Kim, Aurélie Caye-Eude, Céline Chalas, Chrystelle Abdo, Véronique Drouineaud, Régis Peffault de Latour, Marion Alcantara, Madalina Uzunov, Michael Degaud, Véronique Meignin, Hervé Dombret, Nicolas Boissel, Catherine Poirot, Nathalie Dhédin

Blood (2021) 137 (12): 1697–1701.

https://doi.org/10.1182/blood.2020007782

Published: 2021

Includes: Supplemental data

Journal Articles

Myeloid Blast Crisis of Philadelphia Positive Chronic Myeloid Leukemia and Philadelphia Positive Acute Myeloid Leukemia Treated at the AP-HP in Paris: A Retrospective Analysis

Matteo Dragani, MD, Rathana Kim, PharmD, Clémence Loiseau, MD, Madalina Uzunov, MD, Felipe Suarez, MDPhD, Didier Bouscary, MDPhD, Philippe Rousselot, MDPhD, Etienne Lengline, MD, Raphael Itzykson, MD PhD, Jean Michel Cayuela, PhD, Nicolas Boissel, MD PhD, Herve Dombret, MD PhD, Delphine Rea, MDPhD, Emmanuel Raffoux, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-140998

Published: 2020

Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139921

Published: 2020

Journal Articles

A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts

Philippe Rousselot, MDPhD, Clémence Loiseau, MD, Marc Delord, PhD, Caroline Besson, MDPhD, Jean-Michel Cayuela, Marc Spentchian

Blood (2019) 134 (Supplement_1): 27.

https://doi.org/10.1182/blood-2019-129919

Published: 2019

Journal Articles

Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants

Blood (2019) 134 (Supplement_1): 188.

https://doi.org/10.1182/blood-2019-131781

Published: 2019

Journal Articles

Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial

Blood (2019) 134 (Supplement_1): 1295.

https://doi.org/10.1182/blood-2019-124029

Published: 2019

Journal Articles

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Blood (2018) 132 (Supplement 1): 31.

https://doi.org/10.1182/blood-2018-99-114552

Published: 2018

NARROW

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1 + acute lymphoblastic leukemia

Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Chromothripsis and Genomic Complexity As Pejorative Prognostic Markers in Pediatric and Adult T-ALL

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial

IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL

Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia

Myeloid Blast Crisis of Philadelphia Positive Chronic Myeloid Leukemia and Philadelphia Positive Acute Myeloid Leukemia Treated at the AP-HP in Paris: A Retrospective Analysis

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts

Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants

Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only